Asian Stocks Rebound as Trump Delays Iran Strike Deadline 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
9 Tips for Avoiding Tax Season Cyber Scams 
Iran Allows Oil Tankers Through Strait of Hormuz Amid U.S. Negotiations 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Oil Prices Slip as Middle East Tensions Ease, Heading for Weekly Loss 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Bank of Japan Faces Rate Uncertainty Amid Middle East Oil Shock 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
